Dingdang Health Technology Group Ltd. provided earnings guidance for the year ended December 31, 2023. For the year, the Group expects that as (i) the fair value losses on the Company' s preferred shares (which were issued to the Company' s pre-IPO investors) as financial liabilities at fair value through profit or loss and listing expenses did not recur for FY2023 after the completion of the Company's listing of its shares on The Stock Exchange of
Hong Kong Limited in September 2022, and (ii) share-based payments expenses decreased during FY2023, the loss for FY2023 may be narrowed by more than 85% as compared to the loss of RMB 2,842.3 million for the year ended December 31, 2022.